Shandong Center for Disease Control and Prevention, Jinan, Shandong, China.
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Int J Antimicrob Agents. 2017 Apr;49(4):493-497. doi: 10.1016/j.ijantimicag.2016.12.018. Epub 2017 Mar 2.
Since its initial discovery in China in 2015, the plasmid-mediated colistin resistance gene mcr-1 has been reported in Escherichia coli isolated from clinical samples, animals and meat worldwide. In this study, 706 extended-spectrum β-lactamase (ESBL)-producing E. coli from 411 persons were detected in a collection of faecal samples from 1000 rural residents in three counties in Shandong Province, China. These isolates were screened for mcr-1 and phenotypic colistin resistance. The gene was found in 3.5% of the isolates (from 4.9% of persons) from all three counties. All isolates with phenotypic colistin resistance carried mcr-1. These data indicate that commensal carriage of ESBL-producing E. coli with mcr-1 among persons in rural China was already present in 2012 and that mcr-1 was the most important colistin resistance mechanism. Interventions are necessary to minimise further dissemination of mcr-1, which would limit the future usefulness of colistin as a last-resort antibiotic.
自 2015 年在中国首次发现以来,质粒介导的粘菌素耐药基因 mcr-1 已在全球范围内从临床样本、动物和肉类中分离出的大肠杆菌中报道。本研究从山东省三个县的 1000 名农村居民的粪便样本中检测到了 706 株来自 411 人的产超广谱β-内酰胺酶(ESBL)大肠杆菌。这些分离株被筛选 mcr-1 和表型粘菌素耐药性。在来自三个县的所有分离株中,该基因的检出率为 3.5%(来自 4.9%的人)。所有表现出表型粘菌素耐药性的分离株都携带 mcr-1。这些数据表明,2012 年中国农村人群中就已经存在携带 mcr-1 的产 ESBL 大肠杆菌的共生携带,并且 mcr-1 是最重要的粘菌素耐药机制。需要采取干预措施,以尽量减少 mcr-1 的进一步传播,这将限制粘菌素作为最后手段抗生素的未来用途。